JLE

Hématologie

MENU

Pathophysiology and abnormalities of haemostasis in intensive care patients with COVID-19 Ahead of print

  • [1] Li J., Gong X., Wang Z. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. Virus Res. 2020;286:198043.
  • [2] Guan W.J., Ni Z.Y., Hu Y. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
  • [3] Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421-1424.
  • [4] Bikdeli B., Madhavan M.V., Jimenez D. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950-2973.
  • [5] Helms J., Tacquard C., Severac F. High risk of thrombosis in patients with severe Sars-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-1098.
  • [6] Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
  • [7] Lodigiani C., Iapichino G., Carenzo L. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.
  • [8] Joly B.S., Siguret V., Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;46:1603-1606.
  • [9] Varga Z., Flammer A.J., Steiger P. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418.
  • [10] Liu P.P., Blet A., Smyth D., Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142:68-78.
  • [11] Tay M.Z., Poh C.M., Rénia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-374.
  • [12] Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
  • [13] Zhang W., Zhao Y., Zhang F. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
  • [14] Tu W.J., Cao J., Yu L., Hu X., Liu Q. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan. Intensive Care Med. 2020;46:1117-1120.
  • [15] Blanco-Melo D., Nilsson-Payant B.E., Liu W.C. Imbalanced host response to Sars-CoV-2 drives development of Covid-19. Cell. 2020;181:1036-1045e9.
  • [16] Hadjadj J., Yatim N., Barnabei L. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718-724. 6504
  • [17] Iba T., Levy J.H., Connors J.M., Warkentin T.E., Thachil J., Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360.
  • [18] Gupta N., Zhao Y.Y., Evans C.E. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83.
  • [19] Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-847.
  • [20] Panigada M., Bottino N., Tagliabue P. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738-1742.
  • [21] Tabatabai A., Rabin J., Menaker J. Factor VIII and functional protein C activity in critically ill patients with Coronavirus disease 2019: a case series. A A Pract. 2020;14:e01236.
  • [22] Voicu S., Delrue M., Chousterman B.G. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci. 2020;24:9161-9168. 17
  • [23] Griffin J.H., Lyden P. COVID-19 hypothesis: activated protein C for therapy of virus-induced pathologic thromboinflammation. Res Pract Thromb Haemost. 2020;4:506-509. 4
  • [24] Mazzeffi M., Chow J.H., Amoroso A., Tanaka K. Revisiting the protein C pathway: an opportunity for adjunctive intervention in COVID-19? Anesth Analg. 2020;131:690-693. 3
  • [25] Siguret V., Voicu S., Neuwirth M. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Thromb Res. 2020;195:74-76.
  • [26] Devreese K.M.J., Linskens E.A., Benoit D., Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020;18:2191-2201. 9
  • [27] Magro C., Mulvey J.J., Berlin D. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1-13.
  • [28] Khider L., Gendron N., Goudot G. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J Thromb Haemost. 2020;18:2391-2399. 9
  • [29] Guervilly C., Burtey S., Sabatier F. Circulating endothelial cells as a marker of endothelial injury in severe COVID-19. J Infect Dis. 2020;222:1789-1793.
  • [30] Smadja D.M., Guerin C.L., Chocron R. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23:611-620. 4
  • [31] Wichmann D., Sperhake J.P., Lütgehetmann M. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;173:1030. 12
  • [32] Poissy J., Goutay J., Caplan M. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142:184-186.
  • [33] Voicu S., Bonnin P., Stépanian A. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. J Am Coll Cardiol. 2020;76:480-482.
  • [34] Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094-1099.
  • [35] Thachil J., Tang N., Gando S. ISTH interim guidance on recognition and management of coagulopathy in Covid-19. J Thromb Haemost. 2020;18:1023-1026.
  • [36] Chang J.C. Acute respiratory distress syndrome as an organ phenotype of vascular microthrombotic disease: based on hemostatic theory and endothelial molecular pathogenesis. Clin Appl Thromb Hemost. 2019;25:1076029619887437.
  • [37] Fogarty H., Townsend L., Ni Cheallaigh C. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189:1060-1061.
  • [38] Ciceri F., Beretta L., Scandroglio A.M. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22:95-97.
  • [39] Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
  • [40] Chen T., Wu D., Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
  • [41] Wu C., Chen X., Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:1-11.
  • [42] Hardy M., Lecompte T., Douxfils J. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thromb J. 2020;18:17.
  • [43] Ranucci M., Ballotta A., Di Dedda U. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18:1747-1751.
  • [44] Susen S., Tacquard C.A., Godon A. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care. 2020;24:364.
  • [45] Rauch A., Labreuche J., Lassalle F. Coagulation biomarkers are independent predictors of increased oxygen requirements in Covid-19. J Thromb Haemost. 2020;18:2942-2953. 11
  • [46] Pavoni V., Gianesello L., Pazzi M., Stera C., Meconi T., Frigieri F.C. Evaluation of coagulation function by rotation thromboe-lastometry in critically ill patients with severe COVID-19 pneumonia. J Thromb Thrombolysis. 2020;50:281-286.
  • [47] Masi P., Hékimian G., Lejeune M. Systemic inflammatory response syndrome is a major contributor to Covid-19-associa- ted coagulopathy: insights from a prospective single-center cohort study. Circulation. 2020;142:611-614. 6
  • [48] Moores L.K., Tritschler T., Brosnahan S. Prevention, diagnosis, and treatment of VTE in patients with Coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158:1143-1163.
  • [49] Thachil J., Juffermans N.P., Ranucci M. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost. 2020;18:2138-2144.